C7M
A neo-epitope fragment of type VII collagen generated by matrix metalloproteinase activity, enabling non-invasive monitoring of dermal-epidermal junction integrity and tissue remodeling in fibrotic and inflammatory skin disorders.
Key features and values
- Quantifies degradation fragments of type VII collagen produced by matrix metalloproteinase activity.
- Reflects extracellular matrix remodeling associated with dermal-epidermal junction integrity.
- Provides a non-invasive measure of tissue remodeling in fibrotic and inflammatory skin conditions.
- Supports monitoring of disease progression and response to therapies targeting extracellular matrix remodeling.
- Applicable in research on diseases characterized by excessive extracellular matrix turnover, such as systemic sclerosis and atopic dermatitis.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation.
- Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.
Description
The C7M biomarker assay measures specific neo-epitope fragments of type VII collagen generated through matrix metalloproteinase activity, serving as an indicator of extracellular matrix remodeling at the dermal-epidermal junction. This non-invasive assay provides insights into pathological tissue remodeling processes, particularly in conditions such as systemic sclerosis and atopic dermatitis. By quantifying collagen degradation products associated with matrix metalloproteinase activity, the C7M assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tissue remodeling. It serves as a valuable tool in both clinical and research settings for assessing the dynamics of extracellular matrix turnover.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
